Physician profile
Ryan Gregory Toolson
NPI 1841583622
$7,735.42
in general payments reported to CMS, 2019-2025
39 companies · $1,292 in 2025
The $1,292 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $742 · 2020: $422 · 2021: $519 · 2022: $1,419 · 2023: $1,305 · 2024: $2,036 · 2025: $1,292.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,668 · Travel and Lodging: $885 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,667.83 |
| Travel and Lodging | $885.37 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,551.26 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Noah Medical Corporation | $1,062.82 | 2023-2025 | Galaxy |
| Glaxosmithkline, LLC. | $895.79 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| United Therapeutics Corporation | $843.25 | 2019-2025 | Tyvaso, Tyvaso, Orenitram |
| Regeneron Healthcare Solutions, INC. | $438.28 | 2022-2025 | Dupixent |
| Genzyme Corporation | $321.39 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $306.65 | 2019-2024 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Amgen INC. | $244.76 | 2022-2025 | Tezspire |
| Insmed, INC. | $234.23 | 2019-2025 | Arikayce |
| Merck Sharp & Dohme LLC | $217.81 | 2020-2025 | Zerbaxa, Dificid, Recarbrio |
| Grifols USA, LLC | $146.74 | 2019-2024 | Prolastin-C Liquid |
| Mallinckrodt Hospital Products INC. | $126.67 | 2020-2024 | Acthar |
| Mylan Specialty L.P. | $121.70 | 2019-2024 | Yupelri |
| Ethicon INC. | $113.72 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $112.35 | 2019-2023 | Opsumit |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $98.61 | 2020-2025 | Wakix |
| Genentech USA, INC. | $97.46 | 2022-2025 | Xolair |
| Teva Pharmaceuticals USA, INC. | $69.99 | 2020-2022 | |
| Covidien Lp | $69.84 | 2019 | |
| Fisher & Paykel Healthcare INC | $62.14 | 2024-2025 | Fisher & Paykel Healthcare |
| Sanofi-Aventis U.S. LLC | $59.99 | 2023 | |
| Jazz Pharmaceuticals INC. | $56.35 | 2020-2024 | |
| Axsome Therapeutics, INC. | $50.76 | 2022-2023 | Sunosi |
| Philips North America LLC | $43.63 | 2022-2024 | (Ak6) Vest Therapy |
| Csl Behring | $43.02 | 2022-2024 | Kcentra |
| Verona Pharma, INC. | $42.66 | 2025 | Ohtuvayre |
| Pulmonx Corporation | $40.86 | 2024 | Chartis Catheter, Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter |
| Abbvie INC. | $40.75 | 2025 | |
| Inspire Medical Systems, INC. | $36.30 | 2023 | Inspire |
| Inogen, INC. | $33.35 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $26.91 | 2019-2020 | |
| Shire North American Group INC | $19.77 | 2019 | |
| Circassia INC. | $16.50 | 2019 | |
| Nabriva Therapeutics, Plc | $15.88 | 2020 | |
| La Jolla Pharmaceutical Company | $15.64 | 2022 | |
| Pfizer INC. | $15.55 | 2023 | |
| Baxter Healthcare | $15.14 | 2023 | Hillrom - Life 2000 Ventilation System |
| E.R. Squibb & Sons, L.L.C. | $14.20 | 2019 | |
| Sunovion Pharmaceuticals INC. | $12.70 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Toolson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.